ALS Multicenter Cohort Study of Oxidative Stress (ALS COSMOS): Study methodology, recruitment, and baseline demographic and disease characteristics

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Volumn 15, Issue 3-4, 2014, Pages 192-203

  Mitsumoto, Hiroshi ^a   Factor Litvak, Pam ^b   Andrews, Howard ^b   Goetz, Raymond R ^c   Andrews, Leslie ^b   Rabkin, Judith G ^c   Mcelhiney, Martin ^c   Nieves, Jeri ^b,d   Santella, Regina M ^b   Murphy, Jennifer ^e   Hupf, Jonathan ^a   Singleton, Jess ^a   Merle, David ^b   Kilty, Mary ^b   Heitzman, Daragh ^f   Bedlack, Richard S ^g   Miller, Robert G ^h   Katz, Jonathan S ^h   Forshew, Dallas ^h   Barohn, Richard J ⁱ   Sorenson, Eric J ^j   Oskarsson, Bjorn ^k   Fernandes Filho, J Americo M ^l   Kasarskis, Edward J ^m   Lomen Hoerth, Catherine ^e   Mozaffar, Tahseen ⁿ   Rollins, Yvonne D ^o   Nations, Sharon P ^p   Swenson, Andrea J ^q   Shefner, Jeremy M ^r   Andrews, Jinsy A ^s   Koczon Jaremko, Boguslawa A ^s   more..

^a Department of Medicine   (United States)

^b Department of Medicine   (United States)

^c NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^d Clinical Research Center Helen Hayes West Haverstraw   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Texas Neurology   (United States)

^g DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF KANSAS   (United States)

^j MAYO CLINIC   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^m UNIVERSITY OF KENTUCKY   (United States)

ⁿ UNIVERSITY OF CALIFORNIA   (United States)

^o UNIVERSITY OF COLORADO   (United States)

^p UNIVERSITY OF TEXAS   (United States)

^q UNIVERSITY OF IOWA   (United States)

^r SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^s Hospital for Special Care   (United States)

more..

Author keywords

ALS; Disease progression; Epidemiology; Oxidative stress; Survival

Indexed keywords

BIOLOGICAL MARKER; DNA;

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DEMOGRAPHY; DIET; DISEASE ASSOCIATION; DISEASE COURSE; ENVIRONMENTAL FACTOR; FEMALE; HEALTH INSURANCE; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OCCUPATIONAL EXPOSURE; OXIDATIVE STRESS; PATIENT ASSESSMENT; PLASMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOLOGICAL ASPECT; RISK FACTOR; SKIN; STRUCTURED INTERVIEW; STUDY DESIGN; TELEPHONE INTERVIEW; URINE; AGED; CLINICAL TRIAL; COHORT ANALYSIS; GENETICS; INSURANCE; METABOLISM; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PATIENT SELECTION; PHYSIOLOGY; QUESTIONNAIRE; STATISTICS AND NUMERICAL DATA; TIME; UNITED STATES;

AGED; AMYOTROPHIC LATERAL SCLEROSIS; COHORT STUDIES; DEMOGRAPHY; DISEASE PROGRESSION; FEMALE; HUMANS; INSURANCE COVERAGE; MALE; MIDDLE AGED; OXIDATIVE STRESS; PATIENT SELECTION; QUESTIONNAIRES; SKIN; TIME FACTORS; UNITED STATES;

EID: 84901494027     PISSN: 21678421     EISSN: 21679223     Source Type: Journal    
DOI: 10.3109/21678421.2013.864312     Document Type: Article

References (83)

1. D'Amico E, Factor-Litvak P, Santella RM, Mitsumoto H. Clinical perspective of oxidative stress in sproradic ALS. Free Rad Biol Med. 2013;65:50927
2. Andersen JK. Oxidative stress in neurodegeneration: Cause or consequence?. Nature Medicine. 2004;10 (Suppl):S18-25
3. Beckman JS, Estevez AG. S uperoxide dismutase, oxidative stress, and ALS. In: Mitsumoto H, Perzedborski S, Gordon PH, editors. Amyotrophic Lateral Sclerosis. New York: Taylor and Francis;2005. pp 339-54
4. Shaw PJ. M olecular and cellular pathways of neurodegeneration in motor neuron disease. J Neurol Neurosurg Psychiatry. 2005;76:1046-57. (Pubitemid 41081274
5. Martin LJ, Liu Z, Chen K, Price AC, Pan Y, Swaby JA, et al. Motor neuron degeneration in amyotrophic lateral sclerosis mutant superoxide dismutase-1 transgenic mice: Mechanisms of mitochondriopathy and cell death. J Comp Neurol. 2007;500:20-46. (Pubitemid 44904300
6. Pasinelli P, Brown RH. M olecular biology of amyotrophic lateral sclerosis: Insights from genetics. Nat Rev Neurosci. 2006;7:710-23. (Pubitemid 44267495
7. Kaufmann P, Thompson JL, Levy G, Buchsbaum R, Shefner J, Krivickas LS, et al. Phase II trial of CoQ10 for ALS fi nds insuffi cient evidence to justify phase III. Annals of Neurology. 2009;66:235-44
8. Gwinn K, Corriveau RA, Mitsumoto H, Bednarz K, Brown RH Jr, Cudkowicz M, et al. Amyotrophic Lateral Sclerosis: An Emerging Era of Collaborative Gene Discovery. PloSONE. 2007;2:e1234
9. World Federation NRGoAS. A revised El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. 2000; [cited 2013 July 3]. Available from: Www.wfnals.org
10. de Carvalho M, Dengler R, Eisen A, England JD, Kaji R, Kimura J, et al. Electrodiagnostic criteria for diagnosis of ALS. J Clinical Neurophysiol. 2008;3:493-503
11. Cedarbaum J. A LS endpoints. Survival. A myotroph Lateral Scler Other Motor Neuron Disord. 2004;5 (Suppl 1):79-83
12. Gordon PH, Miller RG, Moore DH. A LSFRS-R. A myotroph Lateral Scler Other Motor Neuron Disord. 2004;5 (Suppl 1):90-3
13. Gordon PH, Moore DH, Miller RG, Florence JM, Verheijde JL, Doorish C, et al. Effi cacy of minocycline in patients with amyotrophic lateral sclerosis: A phase III randomized trial. Lancet Neurol. 2007;6:1045-53. (Pubitemid 350116691
14. Miller R, Bradley W, Cudkowicz M, Hubble J, Meininger V, Mitsumoto H, et al. Phase II/III randomized trial of TCH346 in patients with ALS. Neurology. 2007;69:776-84. (Pubitemid 47300935
15. Traynor BJ, Zhang H, Shefner JM, Schoenfeld D, Cudkowicz ME. Functional outcome measures as clinical trial endpoints in ALS. Neurology. 2004;63:1933-5. (Pubitemid 39532394
16. Woolley SC, York MK, Moore DH, Strutt AM, Murphy J, Schulz PE, et al. Detecting frontotemporal dysfunction in ALS: Utility of the ALS Cognitive Behavioral Screen (ALS-CBS □) . Amyotroph Lateral Scler. 2010;11:303-11
17. Rippon GA, Scarmeas N, Gordon PH, Murphy PL, Albert SM, Mitsumoto H, et al. An observational study of cognitive impairment in amyotrophic lateral sclerosis. Arch Neurol-Chicago. 2006;63:345-52
18. Mitsumoto H, Santella RM, Liu X, Bogdanov M, Zipprich J, Wu HC, et al. Oxidative stress biomarkers in sporadic ALS. Amyotrophic lateral sclerosis: Offi cial publication of the World Federation of Neurology Research Group on Motor Neuron Diseases. 2008;9:177-83. (Pubitemid 351983180
19. Dupuis L, Corcia P, Fergani A, d e Aguilar JLG, Bonnefont-Rousselot D, Bittar R, et al. Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology. 2008;70:1004-9
20. Sutedja NA, van der Schouw YT, Fischer K, Sizoo EM, Huisman MHB, Veldink JH, et al. Benefi cial vascular risk profi le is associated with amyotrophic lateral sclerosis. J Neurol Neurosur Ps. 2011;82:638-42
21. Block G, Hartman AM, Naughton D. A reduced dietary questionnaire: Development and validation. Epidemiology. 1990;1:58-64. (Pubitemid 20255624
22. Cummings SR, Block G, McHenry K, Baron RB. E valuation of two food frequency methods of measuring dietary calcium intake. Am J Epidemiol. 1987;126:796-802. (Pubitemid 17161303
23. Nieves JW, Golden AL, Siris E, Kelsey JL, Lindsay R. Teenage and current calcium intake are related to bone mineral density of the hip and forearm in females aged 30-39 years. Am J Epidemiol. 1995;141:342-51
24. Serdula M, Coates R, Byers T, Mokdad A, Jewell S, Chavez N, et al. Evaluation of a brief telephone questionnaire to estimate fruit and vegetable consumption in diverse study populations. Epidemiology. 1993;4:455-63. (Pubitemid 23261379
25. N utritionQuest. 2011. [cited 2013 October 27]. Available from: Https://www.nutritionquest.com/
26. Epel ES, Blackburn EH, Lin J, Dhabhar FS, Adler NE, Morrow JD, et al. Accelerated telomere shortening in response to life stress. Proc Natl Acad Sci U S A. 2004;101:17312-5
27. Epel ES, Lin J, Wilhelm FH, Wolkowitz OM, Cawthon R, Adler NE, et al. Cell aging in relation to stress arousal and cardiovascular disease risk factors. Psychoneuroendocrinology. 2006;31:277-87. (Pubitemid 43261645
28. S apolsky R M. O rganismal stress and telomeric aging: An unexpected connection. Proc Natl Acad Sci U S A. 2004;101:17323-4
29. Albert SM, Rabkin JG, del Bene ML, Tider T, O 'Sullivan I, Rowland LP, et al. Wish to die in end-stage ALS. Neurology. 2005;65:68-74. (Pubitemid 40967778
30. Rabkin JG, Wagner GJ, del Bene M. R esilience and distress among amyotrophic lateral sclerosis patients and caregivers. Psychosom Med. 2000;62:271-9. (Pubitemid 30194215
31. Rabkin JG, Albert SM, del Bene ML, O 'Sullivan I, Tider T, Rowland LP, et al. Prevalence of depressive disorders and change over time in late-stage ALS. Neurology. 2005;65:62-7. (Pubitemid 40967777
32. Lee JR, Annegers JF, Appel SH. P rognosis of amyotrophic lateral sclerosis and the effect of referral selection. J Neurol Sci. 1995;132:207-15
33. Logroscino G, Traynor BJ, Hardiman O, Chio A, Couratier P, Mitchell JD, et al. Descriptive epidemiology of amyotrophic lateral sclerosis: New evidence and unsolved issues. Journal of Neurology, Neurosurgery, and Psychiatry. 2008;79:6-11
34. Chad D, Rowland L, Armon C, Bedlack R, Durham H, Factor-Litvak P. Peer Recommendations 5on How to Improve Clinical Research and Final Conference Wrap-up. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14(Suppl 1):67-73
35. Factor-Litvak P, A l-Chalabi A, Asherio A, Bradley W, Chí oA, Garruto R, et al. Current Pathways for Epidemiological Research in Amyotrophic Lateral Sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14(Suppl 1):33-43
36. Sherman A, Gubitz A, A l-Chalabi A, Bedlack R, Berry J, Conwit R. Infrastructure Resources for Clinical Research in Amyotrophic Lateral Sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14(Suppl 1):53-61
37. Bedlack RS, Pastula DM, Welsh E, Pulley D, Cudkowicz ME. Scrutinizing enrollment in ALS clinical trials: Room for improvement?. Amyotrophic Lateral Sclerosis: Offi cial publication of the World Federation of Neurology Research Group on Motor Neuron Diseases. 2008;9:257-65
38. Bedlack RS, Wicks P, Heywood J, Kasarskis E. M odifi able barriers to enrollment in American ALS research studies. Amyotrophic lateral sclerosis:offi cial publication of the World Federation of Neurology Research Group on Motor Neuron Diseases. 2010;11:502-7
39. Moser DJ, Schultz SK, Arndt S, Benjamin ML, Fleming FW, Brems CS, et al. Capacity to provide informed consent for participation in schizophrenia and HIV research. Am J Psychiatry. 2002;159:1201-7. (Pubitemid 34743262
40. Abrahams S, Leigh PN, Harvey A, Vythelingum GN, Grise D, Goldstein LH. Verbal fl uency and executive dysfunction in amyotrophic lateral sclerosis (ALS). Neuropsychologia. 2000;38:734-47. (Pubitemid 30109452
41. Kertesz A, Nadkarni N, Davidson W, Thomas AW. The Frontal Behavioral Inventory in the differential diagnosis of frontotemporal dementia. J Int Neuropsychol Soc. 2000;6:460-8. (Pubitemid 30394399
42. Smith RA, Berg JE, Pope LE, Thisted RA. M easuring pseudobulbar affect in ALS. Amyotroph Lateral Scler. 2004;5:99-102
43. Kamel F, Umbach DM, Munsat TL, Shefner JM, H uH, Sandler DP. Lead exposure and amyotrophic lateral sclerosis. Epidemiology. 2002;13:311-9
44. Chen HL, Richard M, Sandier DP, Umbach DM, Kamel F. Head injury and amyotrophic lateral sclerosis. American Journal of Epidemiology. 2007;166:810-6. (Pubitemid 47428905
45. Fang F, Quinlan P, Y eW, Barber MK, Umbach DM, Sandler DP, et al. Workplace Exposures and the Risk of Amyotrophic Lateral Sclerosis. Environ Health Persp. 2009;117:1387-92
46. Sorenson EJ, Stalker AP, Kurland LT, Windebank AJ. A myotrophic lateral sclerosis in Olmsted County, Minnesota, 1925 to 1998. Neurology. 2002;59:280-2
47. Mateen FJ, Carone M, Sorenson EJ. P atients who survive fi ve years or more with ALS in Olmsted County, 1925-2004. J Neurol Neurosur Ps. 2010;81:1144-6
48. Horner RD, Grambow SC, Coffman CJ, Lindquist JH, Oddone EZ, Allen KD, et al. Amyotrophic lateral sclerosis among 1991 Gulf War veterans: Evidence for a time-limited outbreak. Neuroepidemiology. 2008;31:28-32
49. Weisskopf MG, McCullough ML, Calle EE, Thun MJ, Cudkowicz M, Ascherio A. Prospective study of cigarette smoking and amyotrophic lateral sclerosis. Am J Epidemiol. 2004;160:26-33. (Pubitemid 38856798
50. Wang H, O 'Reilly EJ, Weisskopf MG, Logroscino G, McCullough ML, Thun MJ, et al. Smoking and risk of amyotrophic lateral sclerosis: A pooled analysis of fi ve prospective cohorts. Arch Neurol. 2011;68:207-13
51. Ascherio A, Weisskopf MG, O 'Reilly EJ, Jacobs EJ, McCullough ML, Calle EE, et al. Vitamin E intake and risk of amyotrophic lateral sclerosis. Annals of Neurology. 2005;57:104-10. (Pubitemid 40053321
52. Weisskopf MG, O'Reilly EJ, McCullough ML, Calle EE, Thun MJ, Cudkowicz M, et al. Prospective study of military service and mortality from ALS. Neurology. 2005;64:32-7
53. Abhinav K, Stanton B, Johnston C, Hardstaff J, Orrell RW, Howard R, et al. Amyotrophic lateral sclerosis in South-East England: A population based study. The South-East England Register for amyotrophic lateral sclerosis (SEALS Registry). Neuroepidemiology. 2007;29:44-8
54. Johnston CA, Stanton BR, Turner MR, Gray R, Blunt AH, Butt D, et al. Amyotrophic lateral sclerosis in an urban setting: A population based study of inner city London. J Neurol. 2006;253:1642-3. (Pubitemid 46116727
55. Popat RA, van den Eeden SK, Tanner CM, Bernstein AL, Bloch DA, Leimpeter A, et al. Effect of reproductive factors and post-menopausal hormone use on the risk of amyotrophic lateral sclerosis. Neuroepidemiology. 2006;27:117-21
56. Popat RA, Tanner CM, van den Eeden SK, Bernstein AL, Bloch DA, Leimpeter A, et al. Effect of non-steroidal antiinfl ammatory medications on the risk of amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis:offi cial publication of the World Federation of Neurology Research Group on Motor Neuron Diseases. 2007;8:157-63
57. Forbes RB, Colville S, Parratt J, Swingler RJ. The incidence of motor neuron disease in Scotland. J Neurol. 2007;254:866-9. (Pubitemid 47222306
58. Chio A, Calvo A, Dossena M, Ghiglione P, Mutani R, Mora G. ALS in Italian professional soccer players: The risk is still present and could be soccer-specifi c. Amyotroph Lateral Scler. 2009;10:205-9
59. Atsuta N, Watanabe H, Ito M, Tanaka F, Tamakoshi A, Nakano I, et al. Age at onset infl uences on wide-ranged clinical features of sporadic amyotrophic lateral sclerosis. J Neurol Sci. 2009;276:163-9
60. Zaldivar T, Gutierrez J, Lara G, Carbonara M, Logroscino G, Hardiman O. Reduced frequency of ALS in an ethnically mixed population. Neurology. 2009;72:1640-5
61. O'Toole O, Traynor BJ, Brennan P, Sheehan C, Frost E, Corr B, et al. Epidemiology and clinical features of amyotrophic lateral sclerosis in Ireland between 1995 and 2004. J Neurol Neurosur Ps. 2008 ;79: 30-2
62. Yeo L, Lynch C, Hardiman O. V alidating population based registers for ALS: How accurate is death certifi cation?. J Neurol. 2010;257:1235-9
63. Phukan J, Elamin M, Bede P, Jordan N, Gallagher L, Byrne S, et al. The syndrome of cognitive impairment in amyotrophic lateral sclerosis: A population based study. J Neurol Neurosurg Psychiatry. 2012;83:102-8
64. Donaghy C, O 'Toole O, Sheehan C, Kee F, Hardiman O, Patterson V. An all-Ireland epidemiological study of MND, 2004-2005. Eur J Neurol. 2009;16:148-53
65. Donaghy C, Clarke J, Patterson C, Kee F, Hardiman O, Patterson V. The epidemiology of motor neuron disease in Northern Ireland using capture-recapture methodology. Amyotroph Lateral Scler. 2010;11:374-8
66. Hanby MF, Scott KM, Scotton W, Wijesekera L, Mole T, Ellis CE, et al. The risk to relatives of patients with sporadic amyotrophic lateral sclerosis. Brain. 2011;134:3454-7
67. Huisman MH, d e Jong SW, van Doormaal PT, Weinreich SS, Schelhaas HJ, van der Kooi AJ, et al. Population based epidemiology of amyotrophic lateral sclerosis using capture-recapture methodology. J Neurol Neurosurg Psychiatry. 2011;82:1165-70
68. de Jong SW, Huisman MH, Sutedja NA, van der Kooi AJ, de Visser M, Schelhaas HJ, et al. Smoking, alcohol consumption, and the risk of amyotrophic lateral sclerosis: A population-based study. Am J Epidemiol. 2012;176:233-9
69. Beghi E, Millul A, Micheli A, Vitelli E, Logroscino G, Group S. Incidence of ALS in Lombardy, Italy. Neurology. 2007;68:141-5
70. Sabatelli M, Conforti FL, Zollino M, Mora G, Monsurro MR, Volanti P, et al. C9orf72 hexanucleotide repeat expansions in the Italian sporadic ALS population. Neurobiol Aging. 2012;33:1848 :e15-20
71. Chio A, Calvo A, Mazzini L, Cantello R, Mora G, Moglia C, et al. Extensive genetics of ALS: A population based study in Italy. Neurology. 2012;79:1983-9
72. C hio A, Calvo A, Moglia C, Gamna F, Mattei A, Mazzini L, et al. Non-invasive ventilation in amyotrophic lateral sclerosis: A 10-year population based study. J Neurol Neurosurg Psychiatry. 2012;83:377-81
73. Chio A, Calvo A, Ghiglione P, Mazzini L, Mutani R, Mora G, et al. Tracheostomy in amyotrophic lateral sclerosis: A 10-year population based study in Italy. J Neurol Neurosurg Psychiatry. 2010;81:1141-3
74. Chio A, Calvo A, Moglia C, Mazzini L, Mora G, group Ps. Phenotypic heterogeneity of amyotrophic lateral sclerosis: A population based study. J Neurol Neurosurg Psychiatry. 2011;82:740-6
75. Logroscino G, Traynor BJ, Hardiman O, Chio A, Mitchell D, Swingler RJ, et al. Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry. 2010;81:385-90
76. Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: The PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA. 1999;282:1737-44
77. Rabkin JG, Struening EL. L ive events, stress, and illness. Science. 1976;194:1013-20
78. Linn MW. A Global Assessment of Recent Stress (GARS) Scale. Int J Psychiatry Med. 1985;15:47-59. (Pubitemid 15063107
79. Endicott J. Q uality of Life Enjoyment and Satisfaction Questionnaire: A new measure. Psychopharmacol Bull. 1993:321-6. (Pubitemid 23311543
80. Watson D, Clark LA, Tellegen A. D evelopment and validation of brief measures of positive and negative affect: The PANAS scales. J Pers Soc Psychol. 1988;54:1063-70
81. Beck AT, Weissman A, Lester D, Trexler L. The measurement of pessimism: The hopelessness scale. J Consult Clin Psych. 1974;42:861-5
82. Manne SL, Taylor KL, Dougherty J, Kemeny N. Supportive and negative responses in the partner relationship: Their association with psychological adjustment among individuals with cancer. J Behav Med. 1997;20:101-25. (Pubitemid 27188123
83. Gift A G. V isual Analog Scales-Measurement of Subjective Phenomena. Nurs Res. 1989;38:286-8. (Pubitemid 19247822.